EFS Depends on Residual Tumor in NSCLC

The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual tumor, suggested analysis.
Medscape Medical News

source https://www.medscape.com/viewarticle/perioperative-pembrolizumab-continues-show-benefit-nsclc-2024a1000gg7?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost